flurbiprofen has been researched along with warfarin in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.23) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 16 (51.61) | 29.6817 |
| 2010's | 13 (41.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Duffy, EM; Jorgensen, WL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Caron, G; Ermondi, G | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Carrupt, PA; Martel, S; Ottaviani, G | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Chiba, K; Goldstein, JA; Guengerich, FP; Inoue, K; Kawai, T; Ozawa, N; Shimada, T; Suzuki, Y; Yamazaki, H | 1 |
| Austin, J; Hage, DS; Kim, HS | 1 |
| Heegaard, NH; Larsen, C; Ostergaard, J; Schou, C | 1 |
| Maftouh, M; Mangelings, D; Massart, DL; Matthijs, N; Tanret, I; Vander Heyden, Y | 1 |
| Gorman, LA; Kumar, V; Rock, DA; Tracy, TS; Wahlstrom, JL; Warren, CJ | 1 |
| Balchen, M; Gjelstad, A; Pedersen-Bjergaard, S; Rasmussen, KE | 1 |
| Jones, JP; Locuson, CW; Tracy, TS; Wienkers, LC | 1 |
| Keseru, GM; Menyhárd, DK; Polgár, T | 1 |
| Cyrankiewicz, M; Kruszewski, S; Wybranowski, T; Ziomkowska, B | 1 |
| Hummel, MA; Mosher, CM; Rettie, AE; Tracy, TS | 1 |
| Bullard, D; Gobbi, A; Kissinger, C; Lardy, MA; Lebrun, L | 1 |
| Deb, R; Dube, D; Nahar, R; Parakh, R; Saxena, R; Singh, TP; Verma, IC | 1 |
| Matsumoto, Y; Matsushita, A; Murayama, N; Shukuya, M; Uno, Y; Yamazaki, H | 1 |
| Inoue, T; Kawano, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
1 review(s) available for flurbiprofen and warfarin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
30 other study(ies) available for flurbiprofen and warfarin
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
Prediction of drug solubility from Monte Carlo simulations.
Topics: Monte Carlo Method; Pharmaceutical Preparations; Solubility | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
Topics: Humans; Membranes, Artificial; Models, Biological; Models, Molecular; Octanols; Permeability; Pharmaceutical Preparations; Skin Absorption; Water | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
Topics: Amino Acid Substitution; Aryl Hydrocarbon Hydroxylases; Catalysis; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Diclofenac; DNA; Flurbiprofen; Heterozygote; Humans; Hydroxylation; Oxidation-Reduction; Polymorphism, Genetic; RNA; Stereoisomerism; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Warfarin | 1998 |
Identification of drug-binding sites on human serum albumin using affinity capillary electrophoresis and chemically modified proteins as buffer additives.
Topics: 2-Hydroxy-5-nitrobenzyl Bromide; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Buffers; Chemical Warfare Agents; Dextrans; Electrophoresis, Capillary; Flurbiprofen; Humans; Ibuprofen; Molecular Structure; Serum Albumin; Suprofen; Tetranitromethane; Tryptophan; Warfarin | 2002 |
Effect of dextran as a run buffer additive in drug-protein binding studies using capillary electrophoresis frontal analysis.
Topics: Buffers; Dextrans; Electrophoresis, Capillary; Flurbiprofen; Humans; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Proteins; Serum Albumin; Warfarin | 2003 |
Separation strategy for acidic chiral pharmaceuticals with capillary electrochromatography on polysaccharide stationary phases.
Topics: Acetonitriles; Buffers; Chromatography, Micellar Electrokinetic Capillary; Electrophoresis, Capillary; Flurbiprofen; Hexobarbital; Hydrogen-Ion Concentration; Ibuprofen; Pharmaceutical Preparations; Polysaccharides; Stereoisomerism; Temperature; Warfarin | 2005 |
CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Diclofenac; Enzyme Inhibitors; Flurbiprofen; Genotype; In Vitro Techniques; Pharmacogenetics; Phenytoin; Piroxicam; Tolbutamide; Warfarin | 2006 |
Electrokinetic migration of acidic drugs across a supported liquid membrane.
Topics: Acids; Chromatography, Micellar Electrokinetic Capillary; Electrophoresis, Capillary; Flurbiprofen; Gemfibrozil; Heptanol; Hydrogen-Ion Concentration; Ketoprofen; Membranes, Artificial; Naproxen; Pharmaceutical Preparations; Probenecid; Reproducibility of Results; Warfarin | 2007 |
CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis.
Topics: Allosteric Regulation; Animals; Aryl Hydrocarbon Hydroxylases; Catalysis; Cytochrome P-450 CYP2C9; Cytochromes b5; Diclofenac; Flurbiprofen; Heme; Humans; Hydrogen Peroxide; Kinetics; Models, Biological; NADP; NADPH-Ferrihemoprotein Reductase; Oxidation-Reduction; Protein Conformation; Rats; Recombinant Proteins; Warfarin; Water | 2007 |
Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets.
Topics: Aryl Hydrocarbon Hydroxylases; Binding Sites; Crystallography, X-Ray; Cytochrome P-450 CYP2C9; Databases, Factual; Flurbiprofen; Humans; Ligands; Models, Molecular; Phylogeny; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Warfarin | 2007 |
The HSA affinity of warfarin and flurbiprofen determined by fluorescence anisotropy measurements of camptothecin.
Topics: Binding, Competitive; Camptothecin; Fluorescence Polarization; Flurbiprofen; Humans; Protein Binding; Serum Albumin; Warfarin | 2008 |
Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9.
Topics: Aryl Hydrocarbon Hydroxylases; Binding Sites; Catalytic Domain; Chromatography, Liquid; Cytochrome P-450 CYP2C9; Flurbiprofen; Kinetics; Magnetic Resonance Spectroscopy; Mutagenesis, Site-Directed; Phenylalanine; Protein Binding; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Warfarin | 2008 |
Building a three-dimensional model of CYP2C9 inhibition using the Autocorrelator: an autonomous model generator.
Topics: Aryl Hydrocarbon Hydroxylases; Computer Simulation; Cytochrome P-450 CYP2C9; Drug Discovery; Enzyme Activation; Enzyme Inhibitors; Flurbiprofen; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Protein Binding; Warfarin | 2012 |
Implication of novel CYP2C9*57 (p.Asn204His) variant in coumarin hypersensitivity.
Topics: Acenocoumarol; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Base Sequence; Binding Sites; Coumarins; Cytochrome P-450 CYP2C9; Female; Flurbiprofen; Genotype; Hemorrhage; Humans; International Normalized Ratio; Middle Aged; Molecular Docking Simulation; Mutation, Missense; Protein Binding; Warfarin | 2013 |
CYP2C19 polymorphisms account for inter-individual variability of drug metabolism in cynomolgus macaques.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Flurbiprofen; Gene Expression Regulation, Enzymologic; Macaca fascicularis; Macaca mulatta; Microsomes, Liver; Models, Molecular; Omeprazole; Polymorphism, Genetic; Protein Conformation; Proton Pump Inhibitors; Warfarin | 2014 |
Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates, S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole.
Topics: Amino Acid Sequence; Animals; Callithrix; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Female; Flurbiprofen; Humans; Macaca fascicularis; Male; Microsomes, Liver; Molecular Sequence Data; Omeprazole; Phylogeny; Species Specificity; Substrate Specificity; Tolbutamide; Warfarin | 2015 |